AI Engines For more Details: Perplexity Kagi Labs You
Gastric Acid Secretion: Histamine H2 receptor agonists, when activated, stimulate the secretion of gastric acid in the stomach. This property has been utilized in the treatment of conditions like gastroesophageal reflux disease (GERD) and peptic ulcers.
Peptic Ulcers: In the past, histamine H2 receptor agonists like cimetidine, ranitidine, and famotidine were commonly used to treat peptic ulcers by reducing gastric acid secretion, thus allowing the ulcer to heal.
Gastroesophageal Reflux Disease (GERD): Histamine H2 receptor agonists have been used to alleviate symptoms of GERD, such as heartburn and acid regurgitation, by reducing the production of gastric acid.
Zollinger-Ellison Syndrome: This is a rare condition characterized by the overproduction of gastric acid. Histamine H2 receptor agonists have been used as part of the treatment regimen to reduce acid secretion and manage symptoms in individuals with this syndrome.
Adverse Effects: While histamine H2 receptor agonists have been generally well-tolerated, they can sometimes cause side effects such as headache, dizziness, diarrhea, and, rarely, more severe adverse effects like liver dysfunction or blood disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Blautia obeum | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0 | 0 | |
| ADHD | 0.7 | 0.1 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | 0 |
| Allergies | 1.1 | 1.3 | -0.18 |
| Allergy to milk products | 0.7 | 0.3 | 1.33 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1 | 2 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.5 | -4 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.5 | 0.7 | -0.4 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.2 | -1 |
| Asthma | 0.3 | 0.4 | -0.33 |
| Atherosclerosis | 0.7 | 0.1 | 6 |
| Atrial fibrillation | 0.7 | 0.3 | 1.33 |
| Autism | 1.7 | 1.1 | 0.55 |
| Autoimmune Disease | 0 | 0.1 | 0 |
| Barrett esophagus cancer | 0.1 | 0.1 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.8 | 0.7 | 0.14 |
| Brain Trauma | 0.1 | 0.7 | -6 |
| Cancer (General) | 0.1 | 0.4 | -3 |
| Carcinoma | 0.9 | 0.7 | 0.29 |
| Celiac Disease | 0.2 | 0.9 | -3.5 |
| Cerebral Palsy | 0.2 | 0.7 | -2.5 |
| Chronic Fatigue Syndrome | 1.5 | 1.7 | -0.13 |
| Chronic Kidney Disease | 1 | 1 | 0 |
| Chronic Lyme | 0 | 0.2 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.2 | -1 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.7 | 0.1 | 6 |
| Colorectal Cancer | 1 | 0.3 | 2.33 |
| Constipation | 0.6 | 0.1 | 5 |
| Coronary artery disease | 0.5 | 0.4 | 0.25 |
| COVID-19 | 1.7 | 2.5 | -0.47 |
| Crohn's Disease | 1.1 | 0.8 | 0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.1 | 0.7 | -6 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 1.7 | 1.8 | -0.06 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.1 | 0.1 | 0 |
| Endometriosis | 0.2 | 0.7 | -2.5 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.2 | 0.1 | 1 |
| erectile dysfunction | 0.1 | 0 | 0 |
| Fibromyalgia | 0.6 | 0.3 | 1 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 1.4 | -1 |
| gallstone disease (gsd) | 0.5 | 0.1 | 4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | 0 |
| Generalized anxiety disorder | 0.2 | 0.3 | -0.5 |
| Gout | 1 | 0.1 | 9 |
| Graves' disease | 0.7 | 0.8 | -0.14 |
| Gulf War Syndrome | 0.1 | 0.1 | 0 |
| Halitosis | 0.2 | 0.2 | |
| Hashimoto's thyroiditis | 1.4 | 0.9 | 0.56 |
| Heart Failure | 0.7 | 0.7 | 0 |
| Hidradenitis Suppurativa | 0.3 | 0.1 | 2 |
| High Histamine/low DAO | 0.1 | 0.5 | -4 |
| hyperglycemia | 0.1 | 0.1 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.1 | 2 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.3 | 1.3 | 0 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.6 | 0.4 | 0.5 |
| Inflammatory Bowel Disease | 1 | 2.2 | -1.2 |
| Insomnia | 0.3 | 0.7 | -1.33 |
| Intelligence | 0.2 | 0.2 | |
| Intracranial aneurysms | 0.6 | 0.1 | 5 |
| Irritable Bowel Syndrome | 1.8 | 0.9 | 1 |
| ischemic stroke | 0.7 | 0.2 | 2.5 |
| Liver Cirrhosis | 1.3 | 1 | 0.3 |
| Long COVID | 1.1 | 2.1 | -0.91 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.2 | 0.5 | -1.5 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.1 | 0.7 | -6 |
| ME/CFS without IBS | 0.1 | 0.4 | -3 |
| Menopause | 0.1 | 0.1 | 0 |
| Metabolic Syndrome | 1.5 | 1.3 | 0.15 |
| Mood Disorders | 1.6 | 1.5 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.8 | 0.9 | -0.13 |
| Multiple system atrophy (MSA) | 0.2 | 0.5 | -1.5 |
| myasthenia gravis | 0.1 | -0.1 | |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.1 | -0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1 | 0.2 |
| NonCeliac Gluten Sensitivity | 0.2 | 0.1 | 1 |
| Obesity | 2.1 | 1.2 | 0.75 |
| obsessive-compulsive disorder | 1.1 | 0.8 | 0.38 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 0.7 | 0.1 | 6 |
| Parkinson's Disease | 2.2 | 1.3 | 0.69 |
| Polycystic ovary syndrome | 1.5 | 1.5 | 0 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| primary biliary cholangitis | 0.1 | 0.1 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.7 | -1.33 |
| Psoriasis | 0.8 | 0.3 | 1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 0.5 | 2.8 |
| Rosacea | 1.1 | 0.1 | 10 |
| Schizophrenia | 1.3 | 0.8 | 0.63 |
| scoliosis | 0.1 | 0.6 | -5 |
| Sjögren syndrome | 0.2 | 0.2 | 0 |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Slow gastric motility / Gastroparesis | 0.6 | 0 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0 | 0 |
| Stress / posttraumatic stress disorder | 0.2 | 0.4 | -1 |
| Systemic Lupus Erythematosus | 0.5 | 0.6 | -0.2 |
| Tic Disorder | 0.5 | 0.1 | 4 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.9 | 0.8 | 0.13 |
| Type 2 Diabetes | 1.3 | 1.2 | 0.08 |
| Ulcerative colitis | 0.8 | 1.3 | -0.63 |
| Unhealthy Ageing | 1.2 | 0.2 | 5 |
| Vitiligo | 0.6 | 0.2 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
